Subscribe
scotus-istock-482156434-1
renaschild / iStockphoto.com
18 May 2021BiotechnologyMuireann Bolger

SCOTUS declines patents review on Enbrel drug

A  Novartis unit,  Sandoz, has failed to persuade the  US Supreme Court to review two Amgen-owned patents on the rheumatoid arthritis drug  Enbrel (etanercept), preventing the roll-out of any copies in the US until 2029.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sandoz fails in Enbrel patent challenge, but Fed Circuit split
2 July 2020   Amgen has won a key patent victory over Sandoz in a dispute over biologic Enbrel.
Americas
Amgen urges Fed Circuit to deny Sandoz petition
27 August 2020   Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Sandoz fails in Enbrel patent challenge, but Fed Circuit split
2 July 2020   Amgen has won a key patent victory over Sandoz in a dispute over biologic Enbrel.
Americas
Amgen urges Fed Circuit to deny Sandoz petition
27 August 2020   Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.

More on this story

Americas
Sandoz fails in Enbrel patent challenge, but Fed Circuit split
2 July 2020   Amgen has won a key patent victory over Sandoz in a dispute over biologic Enbrel.
Americas
Amgen urges Fed Circuit to deny Sandoz petition
27 August 2020   Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers